Soleno Therapeutics (SLNO) Stock Surges After Acquisition News by Neurocrine Biosciences
In a significant move to bolster its rare disease portfolio, Neurocrine Biosciences Inc. (NBIX) has announced the acquisition of Soleno Therapeutics (SLNO). The deal, announced on April 6, 2026, is valued at approximately $2.9 billion, with Neurocrine paying $53 per share to acquire the company according to reports from Maeil Business Newspaper. The acquisition is … Read more